Serum Progranulin Level Might Differentiate Non-IPF ILD from IPF.

Area of Science:

• Pulmonology
• Biomarker Discovery
• Diagnostic Imaging

Background:

• Diagnosing interstitial lung disease (ILD) is complex.
• Serum progranulin (PGRN) has been implicated in liver fibrosis and dermatomyositis-associated acute interstitial pneumonia.
• Identifying reliable biomarkers for ILD diagnosis is crucial.

Purpose of the Study:

• To evaluate the utility of serum progranulin (PGRN) in distinguishing idiopathic pulmonary fibrosis (IPF) from other ILDs.
• To investigate the association between PGRN levels and specific high-resolution computed tomography (HRCT) patterns in ILD.

Main Methods:

• Serum PGRN levels were quantified using enzyme-linked immunosorbent assay (ELISA).
• Measurements were performed in patients with stable IPF (n=40), non-IPF ILD (n=48), and healthy controls (n=17).
• Clinical data, pulmonary function tests, and HRCT findings were analyzed.

Main Results:

• Serum PGRN levels were significantly higher in non-IPF ILD patients compared to healthy controls and IPF patients (p < 0.01).
• IPF patients showed no significant difference in PGRN levels compared to healthy controls.
• Elevated PGRN levels correlated with non-usual interstitial pneumonia (non-UIP) HRCT patterns, while normal levels were associated with UIP patterns.

Conclusions:

• Elevated serum PGRN levels may serve as a biomarker for non-IPF ILDs.
• PGRN could aid in differentiating IPF from other ILDs, especially when radiological patterns are ambiguous.
• Further research is warranted to confirm PGRN's role in ILD diagnosis.